title: Immunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis.
abstract: The aim of the present study was to investigate the role of antinuclear and antiphospholipid antibodies in the pathogenesis of systemic lupus erythematosus (SLE) with demyelinating syndrome and several forms of multiple sclerosis (MS). Paired samples of serum and cerebrospinal fluid (CSF) were investigated using laser nephalometric and enzyme linked immunosorbant assay (ELISA) methods, and the parameters of intrathecal synthesis were calculated. Elevation of the concentrations of antiribosomal P protein antibodies in the CSF and serum, and intrathecal synthesis anticardiolipin (aCL) antibodies were characteristic in all patient groups. The immunoserological changes were more pronounced in the SLE patients. A similar pathogenetic role of antiphospholipid antibodies in central nervous system (CNS) damage in SLE patients with demyelinating syndrome and of MS patients can be assumed.
authors: Department of Neuroimmunology, National Institute of Rheumatology and Physiotherapy, H-1525 Budapest, 114, POB 54, Hungary. kbaraczka@freemail.hu
authors: Kristina
authors: K
authors: Baraczka
authors: G
authors: G
authors: Lakos
authors: S
authors: S
authors: Sipka
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017153:Antibodies, Anticardiolipin / Q000097:blood* / Q000134:cerebrospinal fluid*; D000974:Antibodies, Antinuclear / Q000097:blood* / Q000134:cerebrospinal fluid*; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000473:pathology; D003711:Demyelinating Diseases / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007136:Immunoglobulins / Q000097:blood* / Q000134:cerebrospinal fluid*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011446:Prospective Studies
chemical_list: D000893:Anti-Inflammatory Agents; D017153:Antibodies, Anticardiolipin; D000974:Antibodies, Antinuclear; D007136:Immunoglobulins; D008775:Methylprednisolone